U.S. Stock Market Movement | Most Chinese Biopharmaceutical Stocks Rise, Beigene and Zai Lab Both Up Over 5%
On the evening of October 4th, Chinese biopharmaceutical stocks rose. As of the time of publication, Beigene rose by more than 5%, Zai Lab rose by more than 5%, and Hutchmed China rose by more than 5%. On the news front, recently, influenced by the unexpected policies announced at the State Council Information Office press conference and the Central Political Bureau meeting of the CPC, pharmaceutical stocks have been rallying along with the overall market. Guosen Securities believes that the current growth of the domestic pharmaceutical sector is being driven by both domestic demand and external demand. The improving macro environment both domestically and overseas is creating a favorable external environment for the performance improvement of the pharmaceutical sector. After experiencing the baptism of the epidemic, centralized procurement, anti-corruption, and other challenges, the pharmaceutical sector is expected to enter a new growth cycle in the next 25 years. The industry concentration is expected to accelerate in the coming years, and leading companies will demonstrate stronger alpha characteristics
According to the Wise Finance app, on the evening of October 4th, Chinese biopharmaceutical stocks rose. As of the time of publication, Beigene (BGNE.US) rose by over 5%, Zai Lab (ZLAB.US) rose by over 5%, and Hutchmed China (HCM.US) rose by over 5%.
On the news front, recently, influenced by the unexpected policies announced at the State Council Information Office press conference and the Central Political Bureau meeting of the Communist Party of China, pharmaceutical stocks have been rallying along with the overall market. Guosen Securities believes that the current growth of the domestic pharmaceutical sector is being driven by both domestic demand and external demand. The improving macro environment both domestically and overseas has created a favorable external environment for the performance improvement of the pharmaceutical sector. After experiencing the baptism of the epidemic, centralized procurement, anti-corruption measures, etc., the pharmaceutical sector is expected to enter a new growth cycle in the next 25 years. The industry concentration is expected to accelerate in the coming years, and leading companies will demonstrate stronger alpha attributes